Tagged with R&D

Hong Kong Professor Guangjin Pan, Managing Director of the Centre for Regenerative Medicine and Health (CRMH), discusses how the center’s focuses on translating cutting-edge science into clinical and commercial success – driving Hong Kong’s ambition to become a global biotech hub. As Part of the Hong Kong Institute of Science & Innovation…

Hong Kong A long-standing figure in Hong Kong’s haematology landscape, Professor Kenny Lei has played a pivotal role in advancing lymphoma care and cellular therapies over the past three decades. His contributions span the early adoption of autologous peripheral blood stem cell transplantation and active involvement in establishing the city’s first hospital-based…

Switzerland Nicolas Durand, CEO of Fondation Campus Biotech Geneva, shares insights into the foundation’s unique role as a catalyst for neuroscience and digital health innovation in Switzerland. In this interview, Durand discusses the foundation’s collaborative model, the importance of building critical mass in a specialised domain, and how Fondation Campus Biotech…

Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…

Hong Kong For anyone seeking a place where world-class science and a balanced lifestyle can coexist, Hong Kong offers a uniquely compelling proposition. As China’s pharmaceutical landscape expands into innovative biologics, SPH Biotherapeutics (HK) – an R&D affiliate of Shanghai Pharma – is advancing a dual-targeting CAR-T platform with early clinical results…

Research Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Area Head for Neuroscience at Parexel, shares his insights on the evolving landscape of clinical development for neurological conditions. In this interview, he highlights the importance of localised patient engagement, the role of advocacy in building urgency around diseases like Alzheimer’s, and…

Sweden Even though the development of these treatments takes time, there are many capable people continuing to push the field forward. I believe that lecanemab, BioArctic, and others dedicated to this area will keep innovating, learning, and improving—ultimately leading to better outcomes for patients with Alzheimer’s. Lars Lannfelt, co-founder and board…

USA The Alzheimer’s Drug Discovery Foundation (ADDF) operates in the critical niche of translational research, attempting to bridge the “Valley of Death” between discovery and commercialisation using a venture philanthropy model that reinvests returns into new science. CEO Mark Roithmayr explains how the ADDF has helped launch major diagnostic tools for…

Saudi Arabia Dr Ahmed Alaskar, Executive Director of KAIMRC, provides an update on the development of Saudi Arabia’s growing biotech ecosystem over the past four years. He shares insights into the Kingdom’s National Biotech Strategy and the development of early-stage clinical trial capabilities. Dr. Alaskar also highlights the Kingdom’s unique advantages in…

Puerto Rico DECA is a consulting firm founded in 2022, focused on helping businesses in Puerto Rico access non-dilutive financing incentives, such as federal grants, local grants, and monetizable R&D tax credits. The firm leverages Puerto Rico’s unique financial framework, including Act 60, to streamline the process for both local and foreign…

Europe While Europe has lost some of its global share of clinical trials to China and the US, it remains a clinical research stronghold. Three years into the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to transform how trials are initiated, designed, and run across the…

Denmark A seasoned neuroscience researcher with firsthand experience of both successes and failures in one of biomedicine’s most challenging fields, Johan Luthman is better placed than most to comment on the past, present, and future of Alzheimer’s disease. Luthman, who currently serves as EVP and Head of R&D at Danish neuroscience…